AstraZeneca

New phase 3 trial NCT07291037 posted by AstraZeneca: "Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations". New trial on a phase 3 recruiting study is a moment when external vendors are commonly selected or expanded (spec §70).

Why nowClinicalTrials.gov record updated 4 days ago.

NextMap clinical development and translational medicine stakeholders on the sponsor, confirm no colleague is mid-conversation, then draft evidence-based outreach.

New phase 2 trial NCT03944772 posted by AstraZeneca: "Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)". New trial on a phase 2 active not recruiting study is a moment when external vendors are commonly selected or expanded (spec §70).

Why nowClinicalTrials.gov record updated 586 days ago.

NextHold. Score is below the tenant threshold (55). Keep on the watchlist for follow-on signals.

New phase 3 trial NCT01933932 posted by AstraZeneca: "Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC". New trial on a phase 3 active not recruiting study is a moment when external vendors are commonly selected or expanded (spec §70).

Why nowClinicalTrials.gov record updated 49 days ago.

NextHold. Score is below the tenant threshold (55). Keep on the watchlist for follow-on signals.

New phase 2 trial NCT06008093 posted by AstraZeneca: "A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS". New trial on a phase 2 active not recruiting study is a moment when external vendors are commonly selected or expanded (spec §70).

Why nowClinicalTrials.gov record updated 68 days ago.

NextHold. Score is below the tenant threshold (55). Keep on the watchlist for follow-on signals.

New phase 3 trial NCT07044336 posted by AstraZeneca: "Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)". New trial on a phase 3 recruiting study is a moment when external vendors are commonly selected or expanded (spec §70).

Why nowClinicalTrials.gov record updated 41 days ago.

NextHold. Score is below the tenant threshold (55). Keep on the watchlist for follow-on signals.